Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of BNC210 Compared to Placebo for the Acute Treatment of Social Anxiety Disorder

NCT05193409 is registered in ClinicalTrials.gov with Bionomics Limited as lead sponsor.

NCT NCT05193409
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05193409 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of BNC210 Compared to Placebo for the Acute Treatment of Social Anxiety Disorder
Lead sponsor
Bionomics Limited
Phase
Phase 2
Overall status
Completed
Start date
February 2, 2022
Completion date
October 17, 2022
Enrollment
151 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

social anxiety disorder